Latest news with #SandeepJain
Scroll.in
a day ago
- Politics
- Scroll.in
‘Shows apathy': Allahabad HC raps UP government for delay in disbursing Kumbh stampede compensation
The Allahabad High Court on Friday said that the delay in disbursing compensation to the families of those who died during a stampede at the Maha Kumbh Mela pilgrimage site in Prayagraj showed the Uttar Pradesh government's 'apathy to the plight of the citizens', Live Law reported. A bench of Justices Saumitra Dayal Singh and Sandeep Jain also directed the state government to furnish details of the deaths and medical handling of those who died or were injured between January 28 and the end of the pilgrimage. The Bharatiya Janata Party government in the state was also told to submit details of the number of compensation claims it had received and settled, and those that are pending. The stampede had broken out at the Maha Kumbh on January 29 as a large number of pilgrims arrived to take a holy bath on the occasion of Mauni Amavasya, a spiritually significant day in the Hindu calendar. The state government has said that at least 30 persons were killed and 60 others were injured, although several media reports have suggested that the actual toll could be significantly higher. Uttar Pradesh Chief Minister Adityanath had announced financial assistance of Rs 25 lakh for those who died in the stampede. The court was hearing a plea filed by the husband of one of the persons who died. It expressed concern that the woman's body had been handed over to her family without a postmortem being conducted. The judges took note of the serious injuries reported on the woman, including a crushed rib cage, and questioned the lack of official documentation or communication with the family regarding the cause and circumstances of the death, Live Law reported. The bench directed that medical institutions and authorities in Prayagraj be made parties to the petitions and directed them to file affidavits disclosing details of all patients and dead bodies that may have been brought to the facilities and those dispatched by them between the incident and the end of the Mela. The bench was alarmed that the woman's body was handed over to the family in February but compensation was yet to be provided, according to Live Law.
Fashion Value Chain
28-05-2025
- Business
- Fashion Value Chain
NDR InvIT Grows AUM by 13.3%, Posts Strong FY25 Results
NDR InvIT Trust, India's pioneering perpetual Warehousing and Industrial Parks InvIT listed on the NSE, has announced strong financial and operational results for Q4 and full fiscal year FY25, highlighting sustained growth and stability in India's logistics infrastructure sector. The Trust's Assets Under Management (AUM) expanded by 13.32%, reaching approximately 19.22 million sq. ft. by 31 March 2025. This growth was bolstered by geographic expansion from 13 to 15 cities, underlining NDR InvIT's national footprint and market reach. Operational performance also improved significantly, with warehouse occupancy rising from 95% to 98% and average rentals increasing from INR 17 to INR 18.33/sq. ft./month over the year. The Trust's portfolio now includes 37 industrial parks and over 60 warehouses, with a diversified tenant mix—its top 10 clients contribute only about 33% of rental income, reducing dependency risks. Importantly, only 11.26% of leases are due for renewal in H2 FY26, offering stable revenue visibility. Financially, the Trust posted a Q4 FY25 revenue of INR 945.38 mn and FY25 revenue of INR 3,241.10 mn. Operating EBITDA came in at INR 823.05 mn for Q4 and INR 2,816.99 mn for FY25. Profit after tax (PAT) stood at INR 331.31 mn in Q4 and INR 1,367.30 mn for the year. For Q4 FY25, the Trust declared a distribution of INR 712.82 mn—a 5.79% increase over the previous quarter—equating to INR 1.80 per unit, split into INR 0.72 as interest and INR 1.08 as return of capital. The Net Asset Value (NAV) per unit stood at INR 135.52, with a low loan-to-value (LTV) of 15.8%, reflecting sound financial discipline. Sandeep Jain, CFO of NDR InvIT Trust, commented, 'FY25 was a milestone year with high occupancy, expanding footprint, and increasing returns. We continue to strengthen India's warehousing backbone while delivering consistent value to our stakeholders.' The record date for the Q4 distribution is set on or before 4 June 2025.
The Hindu
26-05-2025
- Health
- The Hindu
11 COVID-19 cases in West Bengal; health workers say no need to panic but urge caution
Eleven active cases of COVID-19 have been reported in West Bengal. Experts have said there is no cause for panic, but people should remain alert and follow basic hygiene and safety protocols to ensure safety and curb any rise in cases. The State Health Department is seeking regular updates on affected patients and, while stating there is no cause for alarm given the low number of reported cases, is closely monitoring the situation. According to sources, several of the patients are seeking medical assistance from local private hospitals. However, a couple of patients who have tested positive for COVID-19 have been recovering at home as the intensity of their infection remained low. Health experts have said that while the overall national caseload remains low, medical professionals warn against complacency, especially in urban areas like Kolkata, where population density, public transport, and frequent gatherings can accelerate transmission. 'Simple practices such as maintaining proper hand hygiene, wearing a mask in crowded areas, and keeping a reasonable distance from others are important. If anyone experiences symptoms of viral fever, they should isolate themselves and seek urgent medical advice. Following government and World Health Organisation (WHO) guidelines, when they are made available, remains essential in keeping ourselves and others safe,' Dr. Sandeep Jain, Associate Consultant at Narayana Superspeciality Hospital, Howrah, said. Doctors have also said that it is crucial to ensure that everyone, especially geriatric patients and people with co-morbidities, receives both vaccine doses and also the booster dose if possible.
Yahoo
21-05-2025
- Business
- Yahoo
FDA Grants IND Clearance for Immunoglobulin Eye Drops to Treat Dry Eye Disease Patients in a Phase II Clinical Study
CHICAGO, May 21, 2025 /PRNewswire/ -- Selagine, Inc., a spin-out company from the University of Illinois Chicago (UIC), announced today that the U.S. Food and Drug Administration (FDA) has granted Investigational New Drug (IND) clearance for immunoglobulin (IG) drops (GRF312 Ophthalmic Solution) for the treatment of patients with dry eye disease (DED). An IG eye drop is an anti-inflammatory and immunomodulatory biologic drug that is generated from pooled human plasma from thousands of healthy donors. In a first-in-human pilot clinical trial conducted at the University of Illinois College of Medicine (UI COM), Department of Ophthalmology & Visual Sciences, immunoglobulin eye drops caused a significant reduction in signs and symptoms of dry eyes with no difference in tolerability or adverse events. In March 2023, Selagine announced a research, development, and sublicense agreement with Grifols, the sponsor of the IND and a global leader in plasma-derived medicines, for the development and commercialization of immunoglobulin eye drops for DED. Initial developmental work for the IG eye drops was performed in the Department of Ophthalmology & Visual Sciences at the UIC College of Medicine and Loyola University, supported by UI Health Pharmacy, and is the outcome of over a decade of research and development efforts, with grant funding from the National Eye Institute (NEI)/National Institutes of Health (NEI R24EY032440), Research to Prevent Blindness and UIC's Office of Technology Management. The Selagine-Grifols sublicense agreement has since been expanded to include the treatment of chemical traumatic injuries with IG eye drops. Inflammatory proteins (cytokines or chemokines), cells (neutrophils, T-cells, and dendritic cells), complement system components, and pathogenic antibodies are present on the ocular surface in chronic dry eye disease; therefore, several different mechanisms of inflammation are simultaneously active and contribute to symptoms and signs of dry eye disease. IG eye drops have beneficial actions on each of these mechanisms, thus providing broad-spectrum anti-inflammatory actions and potentially providing mechanistic superiority over currently approved therapies for chronic dry eye disease. The anti-inflammatory actions of eye drops that are currently approved for treating chronic dry eye disease are narrow-spectrum and limited primarily to targeting T-cell inflammatory mechanisms. "The IND clearance opens the door to clinical trials for establishing the safety and efficacy of IG eye drops and brings us one step closer to meaningfully improving outcomes for people suffering from dry eyes" says Sandeep Jain, MD, Professor of Ophthalmology & Visual Sciences at UIC and Founder and President of Selagine, Inc. "With its strategic commitment to ophthalmics and its global leadership in immunoglobulins, we believe Grifols provides an ideal partner for realizing Selagine's goal of developing the full potential of plasma protein-based eye drops across all ophthalmic indications." "Selagine's success at moving the IG product forward with strong industrial and government partnerships is a testament to UIC's commitment to conducting translational research with multiple applications to benefit patients and providers." Says Suseelan Pookote, PhD, Senior Director of UIC's Office of Technology Management. "With this IND clearance, Selagine's IG product adds to UIC's strong clinical pipeline with eight products in Phase II clinical trials advancing towards the market." "We believe our immunoglobulin eye drops have the potential to make a qualitative leap in how dry eye disease is treated," said Dr. Jörg Schüttrumpf, Grifols Chief Scientific Innovation Officer. "Research suggests that the broad-spectrum anti-inflammatory and immunomodulatory properties of an ocular surface IG are superior to currently approved therapies, including artificial tears and anti-inflammatories. We are using our extensive and deep knowledge of immunoglobulins to benefit the millions of patients globally who aren't receiving sufficient relief". About Dry Eye Disease Dry eye happens when the eyes do not make enough tears to stay wet, or when the tears do not work correctly. This can make the eyes feel uncomfortable, and in some cases it can also cause vision problems. Dry eye affects millions of Americans every year, especially older Americans and women. Autoimmune conditions, such as Sjogren's syndrome, rheumatoid arthritis, Stevens-Johnson syndrome and ocular graft-versus-host-disease are associated with a more severe form of dry eyes. As many as one-third of patients visiting ophthalmology clinics report dry eye symptoms, making it one of the most common conditions seen by ophthalmology specialists. Dry eye disease is the 3rd largest indication of the overall ophthalmology market. The global dry eye market size is projected to reach more than USD 6.5 billion by 2027. For more information about dry eye see: About Selagine Selagine Inc. is a clinical-stage spin-out company from the University of Illinois Chicago (UIC) that is commercializing technology which was developed within the University of Illinois College of Medicine (UI COM), Department of Ophthalmology & Visual Sciences. UI COM places a strong emphasis on supporting faculty efforts toward academic entrepreneurship through initiatives such as the COMassist entrepreneur-in-residence program led by Dr. Michael Flavin. Selagine is focused on developing novel therapeutics to help patients suffering from a variety of debilitating ocular diseases, and to improve the quality of life in conditions where effective therapies do not exist. Selagine's office is located within the Illinois Medical District and its R&D laboratory is housed in UIC's Incubator Laboratory Facility, a hub for entrepreneurship and innovation at the University. For more information, visit About Grifols Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces and provides innovative healthcare services and solutions in more than 110 countries. Patient needs and Grifols' ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company's innovation in both plasma medicines and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across four main therapeutic areas: immunology, infectious diseases, pulmonology and critical care. For more information about Grifols, please visit View original content to download multimedia: SOURCE Selagine, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
&w=3840&q=100)
Business Standard
14-05-2025
- Business
- Business Standard
India to defend import curbs on copper in legal battle with trade groups
The Indian government is expected to argue that there is sufficient domestic supply of copper cathodes, and an adequate number of suppliers, as it prepares a response to a case on import curbs filed by two trade associations, two sources said. India, the world's second-largest importer of refined copper, relies on imports to address shortfalls and meet robust demand in sectors such as energy, defence, automotives and infrastructure. Copper is among the 30 critical minerals identified by India in 2023. But the government imposed quality control measures on copper cathode imports in December, requiring all suppliers, foreign and domestic, to obtain certification from Indian authorities. The Bombay Metal Exchange and the Bombay Non-Ferrous Metals Association have submitted a petition, reviewed by Reuters, to the Bombay High Court claiming that the government action could lead to a monopoly dominated by three domestic suppliers, without naming them. "Where are the shortages?" one of the sources, familiar with government thinking, told Reuters. "The only evidence they (trade bodies) have is that in December and January imports had reduced, which is old data." The source said that companies had imported large quantities of copper in October and November, which then led to lower imports in the following months. "We will fight the case, their case does not hold," the source said, declining to be identified as the government has not filed a formal response yet. Another source confirmed the government would defend its position. The Bombay Metal Exchange was "compelled to seek judicial intervention" as the government did not defer the implementation of the quality control orders, President Sandeep Jain said in a statement. "Given that India relies on imports for approximately 40% of its copper supply, this non-tariff barrier has inevitably led to supply shortages," Jain said, adding that during April to February the copper imports shortfall was 100,000 metric tons compared to the same period last year. India's mines ministry did not respond to request for comment. Demand Surge Copper demand is expected to double by 2030 as India aims to meet the needs of its industries and the energy transition. Domestic companies in the copper industry include Hindalco Industries, Vedanta, Adani, and the state-owned Hindustan Copper. India's refined copper production is estimated at around 555,000 tons per year, and New Delhi imports around 500,000 tons of copper a year to meet the shortfall. Imports have surged since the 2018 closure of Vedanta's domestic Sterlite Copper smelter But in December, the government said that the ramp-up of Adani Enterprises' smelter would fulfil India's domestic requirement and cut down imports. It is expected to become operational over the next four weeks. Japan accounts for about two-thirds of India's refined copper imports, followed by Tanzania and Mozambique. There are currently 10 certified foreign copper suppliers, both sources said, seven of which are Japanese, and five more domestic certified suppliers. (Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
